Treatment of cytomegalovirus retinitis with ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (BW B759U))

JUAN ORELLANA, STEVEN A TEICH, JACQUELINE S WINTERKORN, USHA MATHUR-WAGH, SANDRA HANDWERGER, HARAN SCHLAMM, STEPHEN C MALAMUD, STANLEY R YANCOVITZ, DONNA M CEDERBERG, AND DONNA S MILDVAN

From the 1Department of Ophthalmology, Beth Israel Medical Center, and the Mount Sinai School of Medicine; 2Division of Infectious Diseases, Beth Israel Medical Center; and 3Burroughs Wellcome Company

SUMMARY Six patients (11 eyes) with virologically confirmed cytomegalovirus (CMV) retinitis involving the posterior pole of the eye were treated with a new drug, ganciclovir. Treatment with intravenous ganciclovir consistently halted progression of retinitis and produced improvement in measures of visual function. However, within three weeks after cessation of therapy renewed CMV activity and worsening of visual function were observed in most cases. Maintenance therapy with ganciclovir extended the period of remission from CMV retinitis.

The acquired immunodeficiency syndrome (AIDS) is an epidemic disorder characterised by immunological impairment that predisposes to the development of cancer and to life threatening infections with opportunistic organisms. The syndrome, first reported in homosexual men, and subsequently in intravenous drug abusers, recent Haitian immigrants, haemophiliacs, transfusion recipients, and infants of women in known risk groups for AIDS, has been well documented since 1981.1,2 Opportunistic infections including Pneumocystis carinii pneumonia, oral and esophageal candidiasis, herpes simplex, herpes zoster, cytomegalovirus, systemic cryptococcus, atypical mycobacterial infections, and toxoplasmosis as well as Kaposi’s sarcoma and non-Hodgkin’s lymphoma are frequently seen in these patients.1,7

Cytomegalovirus (CMV), a common and often severe opportunistic infection in these patients, may be present in the retina in the absence of clinically apparent cytomegalovirus infection elsewhere. The retinal manifestations of CMV are retinal necrosis with haemorrhages, exudates, retinal vasculitis, and a slow but steady progression to complete retinal destruction.8,9

There is no efficacious treatment for either ocular or systemic cytomegalovirus infections. A new experimental intravenous drug, ganciclovir (BW B759U or 9-[2-hydroxy-1-(hydroxy-methyl) ethoxymethyl] guanine), an analogue of acyclovir, is being evaluated for the treatment of patients with CMV retinitis. This report describes an initial series of patients with AIDS and CMV retinitis who have received this new agent.

Materials and methods

The cases reported are the first six patients (11 eyes) with AIDS and CMV retinitis who consented to treatment at the Beth Israel Medical Center (BIMC) with the drug ganciclovir. The patients included five men and one woman, ranging in age from 29–55, and all with history of homosexuality or intravenous drug abuse and a diagnosis of AIDS. All patients had positive urine cultures for CMV as well as increased serological titres for CMV. At the start of treatment their visual acuities ranged from 20/30 to no light perception (Table 1). All patients had disease involving the posterior pole, that is, involvement of either or both the macula and optic nerve.
Table 1 Visual acuity after 21 days of therapy

<table>
<thead>
<tr>
<th>Patient</th>
<th>Before therapy</th>
<th>After therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>LP with projection OS</td>
<td>20/30 OS</td>
</tr>
<tr>
<td>2</td>
<td>20/30 OD</td>
<td>NLP OD</td>
</tr>
<tr>
<td>3</td>
<td>20/50 OS</td>
<td>20/30 OS</td>
</tr>
<tr>
<td>4</td>
<td>CF at 2-4 m OD</td>
<td>20/200 OD</td>
</tr>
<tr>
<td>5</td>
<td>NLP OD</td>
<td>NLP OD</td>
</tr>
<tr>
<td>6</td>
<td>20/100 OD</td>
<td>20/70 OD</td>
</tr>
</tbody>
</table>

NPL = no light perception. LP = light perception. CF = counting fingers. HM = hand motions.

Complete blood counts including platelet counts, blood chemistries including liver function tests, electrolytes, blood urea nitrogen, and serum creatinine were obtained prior to initiating treatment and followed up at least every three days during therapy. In two patients on maintenance therapy these tests were performed once each week.

A complete ophthalmological examination was performed which included visual acuity testing, external and slit-lamp examination, intraocular pressure determination, and funduscopic evaluation. A baseline fluorescein angiogram, electroretinogram, and visual evoked response were performed on all patients. All patients received a baseline macular function test by the macula program of the Humphrey automated perimeter.

While in the hospital the patients had daily eye examinations, with fundus photography performed every third day. Macular function tests were repeated at least weekly, and fluorescein angiograms were repeated on a weekly basis.

All patients received ganciclovir 2.5 mg/kg intravenously every eight hours for a 21-day course. Two patients received more than one course in hospital. Two of the patients received subsequent maintenance therapy after finishing the 21-day course. It consisted of 5 mg/kg intravenously once per day for
Treatment of cytomegalovirus retinitis with ganciclovir

had both bilateral progressive scarring of the posterior pole and optic atrophy, resulting in a final visual acuity of no light perception. Thus ganciclovir improved or stabilised 81-7% of treated eyes. Two patients relapsed and required subsequent therapy more than once and lost an additional line of acuity on the Snellen chart; however, their final acuities remained better than their pretherapy acuities.

All patients had a drop in their white blood cell counts. In one case the dose of ganciclovir was decreased to 1 mg/kg intravenously every eight hours while the patient remained absolutely neutropenic (less than 1×10⁶ white cells/l), and in another case the drug was terminated. The liver function values increased in five of the six patients; however, this did not interfere with the therapy regimen. Three of the six patients died after therapy, one from toxoplasmosis and two from disseminated CMV. One was lost to follow-up. Three patients had not received maintenance therapy because they refused any further medications. One patient died from septicaemia while on maintenance therapy.

Discussion

Active CMV infection can be diagnosed by an increase in complement fixation antibodies, culture of the virus in serum, urine, saliva, or other body fluids, or biopsy confirmation of cells showing the classic histopathological picture. In the eye the virus has been isolated from tears¹¹ or conjunctiva¹² of patients with and without retinitis and does not correlate well with ocular symptoms. In patients with retinitis cultures of subretinal fluid and vitreous may be positive.¹³⁺¹⁶ In patients with panuveitis aqueous taps have yielded live virus.¹⁹⁻²⁰ On occasion the diagnosis can be made by a vitreous tap and culture.²⁰⁻²⁴ CMV retinitis has been found in 15% to 46% of AIDS patients in most series from the United States.¹⁸⁻²² Once observed in these patients, the retinitis tends to be slowly but inexorably progressive, often affecting both eyes and ultimately causing complete blindness.

Therapy for cytomegalovirus retinitis has been for the most part unsuccessful. Limited experiences with transfer factor¹⁴ and antiviral drugs such as adenine arabinoside,²¹ floxacine, and acyclovir have yielded only an occasional report of success.²⁵⁻²⁷ Clinically treatment with ganciclovir also did not appear to provide a permanent cure in the present series. Although this agent consistently halted the progression of the retinitis several days after initiation, and improved both the vision and the retina, these effects were maintained only during therapy and for a short time after drug therapy was withdrawn.²⁸⁻³¹

Approximately three weeks after completion of a

Results

We found that six of 11 eyes (54.5%) improved their visual acuity by at least one line on the Snellen chart by the end of the 21-day course (Table 1. Figs. 1–5). Three eyes (27.2%) remained stable at pretherapy acuities and two eyes (18.1%) deteriorated. Patient 2

Fig. 4 After 10 days of therapy there is still some mild residual oedema of macula, and some borders of the optic nerve are now clearly visible. The acuity was 20/200.

five of seven days every week administered through a Broviac catheter placed into a subclavian vessel.

Fig. 5 While on maintenance therapy the fundus significantly cleared. The visual acuity progressed to 20/30 in the right eye. The patient reported a great sense of wellbeing while on maintenance therapy.
typical 21-day course, renewed CMV activity was observed in the retinas of cases 1, 2, 4, and 5.

Ganciclovir or BW B759U is an acyclic nucleoside analog of acyclovir. It is active against herpes simplex types I and II (HSV), varicella zoster virus (V2V), Epstein-Barr virus (EBV), and human cytomegalovirus (HCMV). In studies on human cytomegalovirus of strain AD169, BW B759U did not appear to affect virus early gene function. However, the synthesis of several late structural proteins was inhibited. It appears that ganciclovir is incorporated by intranucleotide linkage into the DNA extracted from HSV infected cells. This suggests that it does not function as a chain terminator as does acyclovir. Ganciclovir strongly inhibits the synthesis of viral DNA in human cytomegalovirus infected cells as well as in herpes simplex virus infected cells. In essence this new drug is phosphorylated and eventually functions as an alternative substrate, as a competitive inhibitor of the human cytomegalovirus induced DNA polymerase.

The main toxic effects of ganciclovir include reversible bone marrow depression and irreversible testicular atrophy. Assays done on the drug show that the toxicity falls between that of vidarabine and that of acyclovir. However, in patients with AIDS, HTLV-III/LAV virus also produces cytopenias and may synergistically act to decrease the white blood cell count, complicating evaluation of drug toxicity in these patients. Drug toxicity is believed to be minimal at 2.5 mg/kg. At a dose of 5 mg/kg bone marrow suppression may occur. At a dosage of 7 mg/kg per day in animal models testicular atrophy occurred. At dosages of 20 mg/kg per day diarrhoea and emesis occurred in addition to cytostatic effects (bone marrow, thymus, lymphoid organs) and testicular atrophy. At large doses of 60 mg/kg per day animals experienced diarrhoea and emesis, cytostatic effects, testicular atrophy, maturation arrest of gastrointestinal cells, and death.

In the early patients reported here, no side effects were noted other than a decrease in the white blood cell count. In most patients it decreased slightly, and in two the treatment was reduced or stopped until the white blood cell count returned to normal. One case (3) experienced a transient decrease in the white blood cell count several days after finishing a first 10-day course of therapy. It could not be determined, however, whether this represented a delayed effect of the ganciclovir therapy or a consequence of other concurrent medications, the direct effect of the CMV itself, or the underlying immune deficiency. More interesting was that many of these patients stated they had an improved feeling of general wellbeing while on the drug. Those patients who had headaches noted improvement while on therapy. One can theorise that the medication may be able to enter the central nervous system and inhibit the virus despite animal studies suggesting poor CNS penetration.

Ganciclovir appears to slow or halt progression of CMV retinitis and allow for healing and visual improvement as shown by fundus photographs and macular fields. However, after therapy is discontinued the retinitis recurs, usually within three weeks. In addition recurrent episodes of CMV retinitis appear to respond more slowly and incompletely to treatment than do the initial episodes. As a result of the experience we report here, patients are being put on a maintenance schedule of 5 mg/kg intravenously in one dose, five times a week, after the initial course of therapy is completed. It is hoped that such a regimen will prevent recurrent retinitis.

The authors express their thanks to Burroughs Wellcome Company for providing them with the drug BW B759U.

References
Treatment of cytomegalovirus retinitis with ganciclovir

36 Burroughs Wellcome Company Document TTEP/84/0016. Accepted for publication 23 April 1987.
Treatment of cytomegalovirus retinitis with ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (BW B759U).

J Orellana, S A Teich, J S Winterkorn, U Mathur-Wagh, S Handwerger, H Schlamm, S C Malamud, S R Yancovitz, D M Cederberg and D S Mildvan

doi: 10.1136/bjo.72.7.525